Orthofix Announces Appointment of Vickie Capps to Board of Directors
Orthofix Medical (NASDAQ:OFIX) has appointed Vickie Capps to its Board of Directors, effective March 11, 2025. This strategic addition expands the board to ten members, bringing diverse expertise in global business operations, strategic development, and corporate finance.
Capps, a Certified Public Accountant with a B.S. in business administration from San Diego State University, brings significant experience from her role as former CFO of DJO Global, Inc. She currently serves on multiple boards, including Amedisys, Inc., Janux Therapeutics, Inc., Enable Injections, Inc., and Breg, Inc. She is also a member of the Senior Advisory Board of Consonance Capital Partners.
The appointment aligns with Orthofix's strategic transformation aimed at delivering profitable growth and sustainable shareholder value in the medical technology sector, focusing on musculoskeletal pathologies.
Orthofix Medical (NASDAQ:OFIX) ha nominato Vickie Capps nel suo Consiglio di Amministrazione, con effetto dall'11 marzo 2025. Questa aggiunta strategica espande il consiglio a dieci membri, portando una diversità di competenze nelle operazioni commerciali globali, nello sviluppo strategico e nella finanza aziendale.
Capps, Dottore Commercialista con una laurea in amministrazione aziendale presso la San Diego State University, porta con sé un'esperienza significativa dal suo ruolo di ex CFO di DJO Global, Inc. Attualmente, è membro di diversi consigli, tra cui Amedisys, Inc., Janux Therapeutics, Inc., Enable Injections, Inc. e Breg, Inc. È anche membro del Senior Advisory Board di Consonance Capital Partners.
La nomina è in linea con la trasformazione strategica di Orthofix, mirata a garantire una crescita profittevole e un valore sostenibile per gli azionisti nel settore della tecnologia medica, con un focus sulle patologie muscoloscheletriche.
Orthofix Medical (NASDAQ:OFIX) ha nombrado a Vickie Capps en su Junta Directiva, con efecto a partir del 11 de marzo de 2025. Esta adición estratégica expande la junta a diez miembros, aportando una diversidad de experiencia en operaciones comerciales globales, desarrollo estratégico y finanzas corporativas.
Capps, Contadora Pública Certificada con una licenciatura en administración de empresas de la Universidad Estatal de San Diego, aporta una experiencia significativa de su papel como ex CFO de DJO Global, Inc. Actualmente, forma parte de varias juntas, incluyendo Amedisys, Inc., Janux Therapeutics, Inc., Enable Injections, Inc. y Breg, Inc. También es miembro del Consejo Asesor Senior de Consonance Capital Partners.
La nominación se alinea con la transformación estratégica de Orthofix, destinada a lograr un crecimiento rentable y un valor sostenible para los accionistas en el sector de la tecnología médica, enfocándose en patologías musculoesqueléticas.
Orthofix Medical (NASDAQ:OFIX)는 Vickie Capps를 이사회의 일원으로 임명했으며, 이는 2025년 3월 11일부터 효력을 발휘합니다. 이 전략적 추가로 이사회는 10명으로 확대되며, 글로벌 비즈니스 운영, 전략 개발 및 기업 재무 분야에서 다양한 전문성을 제공합니다.
Capps는 샌디에이고 주립대학교에서 경영학 학사 학위를 취득한 공인 회계사로, DJO Global, Inc.의 전 CFO로서 상당한 경험을 가지고 있습니다. 현재 Amedisys, Inc., Janux Therapeutics, Inc., Enable Injections, Inc. 및 Breg, Inc. 등 여러 이사회의 일원으로 활동하고 있습니다. 또한 Consonance Capital Partners의 고문위원회에도 소속되어 있습니다.
이번 임명은 근골격계 질환에 중점을 둔 의료 기술 분야에서 수익성 있는 성장과 지속 가능한 주주 가치를 제공하기 위한 Orthofix의 전략적 변혁과 일치합니다.
Orthofix Medical (NASDAQ:OFIX) a nommé Vickie Capps au sein de son Conseil d'Administration, avec effet au 11 mars 2025. Cet ajout stratégique élargit le conseil à dix membres, apportant une expertise diversifiée dans les opérations commerciales mondiales, le développement stratégique et la finance d'entreprise.
Capps, expert-comptable certifiée avec un B.S. en administration des affaires de l'Université d'État de San Diego, apporte une expérience significative de son rôle d'ancienne CFO de DJO Global, Inc. Elle siège actuellement dans plusieurs conseils, notamment ceux d'Amedisys, Inc., Janux Therapeutics, Inc., Enable Injections, Inc. et Breg, Inc. Elle est également membre du Conseil Consultatif Senior de Consonance Capital Partners.
Cette nomination s'inscrit dans la transformation stratégique d'Orthofix visant à offrir une croissance rentable et une valeur durable pour les actionnaires dans le secteur de la technologie médicale, en se concentrant sur les pathologies musculosquelettiques.
Orthofix Medical (NASDAQ:OFIX) hat Vickie Capps in seinen Vorstand berufen, mit Wirkung zum 11. März 2025. Diese strategische Ergänzung erweitert den Vorstand auf zehn Mitglieder und bringt vielfältige Expertise in globalen Geschäftsoperationen, strategischer Entwicklung und Unternehmensfinanzierung mit sich.
Capps, eine zertifizierte Wirtschaftsprüferin mit einem B.S. in Betriebswirtschaft von der San Diego State University, bringt umfassende Erfahrung aus ihrer Rolle als ehemalige CFO von DJO Global, Inc. mit. Derzeit ist sie in mehreren Vorständen tätig, darunter Amedisys, Inc., Janux Therapeutics, Inc., Enable Injections, Inc. und Breg, Inc. Außerdem ist sie Mitglied des Senior Advisory Boards von Consonance Capital Partners.
Die Ernennung steht im Einklang mit der strategischen Transformation von Orthofix, die darauf abzielt, profitables Wachstum und nachhaltigen Shareholder-Wert im Bereich der Medizintechnologie zu liefern, mit einem Fokus auf muskuloskelettale Erkrankungen.
- Strategic board addition bringing expertise in global operations, business development, and corporate finance
- Appointment of experienced healthcare industry executive with extensive board experience
- Expansion of board diversity and expertise in medical technology sector
- None.
Vickie Capps (Photo: Business Wire)
“Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix,” said Michael Finegan, Chairman of Orthofix. “Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significant, sustainable shareholder value and fulfill our vision to be the unrivaled partner in med tech delivering exceptional experiences and life-changing solutions. We are thrilled to welcome Vickie to the Orthofix team.”
Ms. Capps has had a distinguished career in finance and executive leadership with extensive board experience. In addition to Orthofix, Ms. Capps is currently a member of the board of directors and the audit committee of each of the following companies: Amedisys, Inc., a public home healthcare company, Janux Therapeutics, Inc., a public clinical stage biotechnology company, Enable Injections, Inc., a private medical device company focused on wearable drug delivery solutions, and Breg, Inc., a private medical device company focused on non-surgical orthopedic rehabilitation. She is also a member of the Senior Advisory Board of Consonance Capital Partners, a healthcare focused private equity firm. She previously served as a member of the boards of directors of NuVasive, Inc., Otonomy, Inc., Silverback Therapeutics, Inc., OmniGuide Holdings, Synthorx, Inc., Enclara Pharmacia, Connecture, Inc., RF Surgical Systems and SenoRx. She is also a member of the board of directors of the San Diego State University Research Foundation. Ms. Capps previously served as chief financial officer of DJO Global, Inc., a global orthopedics company, from 2002 to 2013. She is a Certified Public Accountant, and she received her B.S. in business administration and accounting from San Diego State University.
“I am honored to join the Board of Directors at this important point in Orthofix’s strategic transformation,” said Vickie Capps. “I am inspired by the Company’s mission to provide medical technologies that heal musculoskeletal pathologies and look forward to working with the Board and leadership team to drive profitable growth and maximize value creation.”
The appointment of Vickie Capps increases the size of Orthofix's Board to ten members with a wide range of business, medical device and healthcare backgrounds.
Internet Posting of Information
Orthofix routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.orthofix.com. The Company encourages investors and potential investors to consult the Orthofix website regularly for important information about Orthofix.
About Orthofix
Orthofix is a global medical technology company headquartered in
Forward-Looking Statements
This news release may include forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” “continue” or other comparable terminology. Orthofix cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Each forward-looking statement contained in this news release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risks identified under the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K filed with the SEC. The Company’s public filings with the SEC are available at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Orthofix does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250312538957/en/
Investors and Media
Julie Dewey, IRC
Chief Investor Relations & Communications Officer
JulieDewey@Orthofix.com
209.613.6945
Source: Orthofix Medical Inc.
FAQ
When will Vickie Capps join Orthofix (OFIX) Board of Directors?
How many members will be on Orthofix's (OFIX) Board after Vickie Capps' appointment?
What is Vickie Capps' professional background before joining Orthofix (OFIX)?
What expertise does Vickie Capps bring to Orthofix's (OFIX) Board?
